ArticleTargeted oncology2023

Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.

Yen-Hsiang Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.